No data to show
XNAS
SRZNW
Market cap97kUSD
May 20, Last price
0.03USD
1Q
74.42%
IPO
-98.38%
Name
Surrozen Inc
Chart & Performance
P/E
—
P/S
0.01
EPS
—
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
11m
Net income
-64m
L+47.68%
CFO
-18m
L-56.33%
Profile
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies to engage the body's existing biological repair mechanisms with potential application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043 that stimulates hepatocyte regeneration, improves liver function, and reduces fibrosis; and SZN-1326, a bi-specific full-length human antibody that directly modulates Wnt signaling in target tissue by binding to particular Frizzled and LRP receptors that are highly expressed in intestinal crypts. The company was founded in 2016 and is headquartered in South San Francisco, California.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | |
| Income | |||||
Revenues | 10,655 | 12,500 | |||
Cost of revenue | 36,194 | 70,258 | 56,839 | ||
Unusual Expense (Income) | |||||
NOPBT | (25,539) | (70,258) | (44,339) | ||
NOPBT Margin | |||||
Operating Taxes | (8,335) | ||||
Tax Rate | |||||
NOPAT | (25,539) | (70,258) | (36,004) | ||
Net income | (63,564) 47.68% | (43,042) 55.56% | (27,669) -47.31% | ||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | 16,043 | (59) | (2,607) | ||
BB yield | -25,559.94% | 150.71% | |||
| Debt | |||||
Debt current | 1,829 | 4,994 | 2,226 | ||
Long-term debt | 15,109 | 4,261 | 8,978 | ||
Deferred revenue | |||||
Other long-term liabilities | 55,892 | 115 | 326 | ||
Net debt | (17,627) | (26,788) | (64,634) | ||
| Cash flow | |||||
Cash from operating activities | (17,628) | (40,363) | (44,145) | ||
CAPEX | (26) | (398) | (728) | ||
Cash from investing activities | (26) | 51,723 | 38,309 | ||
Cash from financing activities | 16,176 | 276 | (2,565) | ||
FCF | (25,938) | (71,324) | (33,526) | ||
| Balance | |||||
Cash | 34,565 | 36,043 | 75,838 | ||
Long term investments | |||||
Excess cash | 34,032 | 36,043 | 75,213 | ||
Stockholders' equity | (285,259) | (221,695) | (178,891) | ||
Invested Capital | 328,240 | 266,792 | 260,820 | ||
ROIC | |||||
ROCE | |||||
| EV | |||||
Common stock shares outstanding | 2,933 | 2,018 | 34,722 | ||
Price | 0.02 10.31% | 0.02 | |||
Market cap | 63 60.33% | 39 | |||
EV | (17,564) | (26,749) | |||
EBITDA | (24,097) | (68,347) | (42,384) | ||
EV/EBITDA | 0.73 | 0.39 | |||
Interest | 1,955 | ||||
Interest/NOPBT | |||||